By Lauren Berg
Long-running multidistrict litigation over AbbVie and Teva Pharmaceuticals' agreement to delay generic forms of cholesterol drug Niaspan is headed toward trial, after a Pennsylvania federal judge Friday found a genuine dispute over whether their agreement was a pay-to-delay settlement that violated antitrust laws.
Read Full Article